GO Main Menu Go Main Contents Go Bottom Menu

CelltrionHealthcare

gnb show

MENU

Gnb close

Press Release

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients 2023-12-11

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients   Ventegra® will list VEGZELMA®(bevacizumab-adcd) on its national formulary that serves more than 400 clients and more than 13 million members and patients in the U.S. Celltrion USA completes a contract ...

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs 2023-10-26

Celltrion USA announces distribution and incorporation of YUFLYMA® (adalimumab-aaty), a Humira® biosimilar, to CarePartners Specialty Pharmacy Cost Savings Programs YUFLYMA® (adalimumab-aaty) was first approved by the Food and Drug Administration on May ...

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease 2023-10-23

Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA™ (infliximab-dyyb), the First and Only Subcutaneous infliximab, for the Treatment of People With Inflammatory Bowel Disease ZYMFENTRA™ is the first and only FDA-approved subcutaneous (SC) formulation of i...

게시물 검색
  • 55
    European Commission grants marketing authorisation..
    European Commission grants marketing authorisation for world’s first subcutaneous formulation of infliximab, Remsima®SC, for an additional five indications including for use in inflammatory bowel disease and ankylosing spondylitis The European…
    2020-07-27
  • 54
    Celltrion Launches Human Clinical Trial of Potenti..
    Celltrion launches human clinical trial of potential COVID-19 antiviral antibody treatment following positive pre-clinical results ·The Phase I study of Celltrion’s COVID-19 antiviral antibody treatment candidate in healthy volunteers is set for co…
    2020-07-17
  • 53
    Celltrion Healthcare receives positive CHMP opinio..
    Celltrion Healthcare receives positive CHMP opinion for an additional five indications for Remsima® SC including for use in inflammatory bowel disease and ankylosing spondylitis ·The positive Committee for Medicinal Products for Human Use (CHMP) opi…
    2020-06-29
  • 52
    Celltrion to expand COVID-19 testing portfolio to ..
    Celltrion to expand COVID-19 testing portfolio to include both antigen and antibody testing kits Celltrion plans to launch point-of-care antigen testing (POCT) kit in July in collaboration with BBB, a South Korean healthcare techno…
    2020-06-16
  • 51
    New Phase II data indicate regimen of Truxima® (bi..
    New Phase II data indicate regimen of Truxima®(biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma Data from a Phase II trial show a regimen o…
    2020-06-15
  • 50
    Celltrion Healthcare showcases positive 1-year dat..
    Celltrion Healthcare showcases positive 1-year data and budget impact analysis for novel subcutaneous formulation of infliximab in patients with rheumatoid arthritis at the European E-Congress of Rheumatology 2020 1-year data from a ran…
    2020-06-04
  • 49
    Celltrion announces positive pre-clinical results ..
    Celltrion announces positive pre-clinical results for COVID- 19 antiviral antibody treatment, showing improvement in recovery time ·Pre-clinical data for Celltrion’s antiviral antibody treatment candidate demonstrate a 100-fold reduction in viral lo…
    2020-06-01
  • 48
    New data show first-line triplet regimen of pembro..
    New data show first-line triplet regimen of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer Data from a phase Ib/II trial show a first-line triple combination…
    2020-05-29
  • 47
    Celltrion completes neutralisation test on candida..
    Celltrion completes neutralisationtest on candidate monoclonal antibodies (mAbs) for COVID-19 antiviral antibody treatment ·Celltrion completes selection of therapeutic antibodies which are most potent for neutralising the virus ·Celltrion expects …
    2020-04-13
  • 46
    Celltrion’s COVID-19 Antiviral Treatment Enters th..
    Celltrion’s COVID-19 antiviral treatment enters the next phase of development ·Celltrion initiates the 2nd stage; selecting the therapeutic antibodies which are most potent for neutralising the infection ·Celltrion completed the 1st phase of screen…
    2020-04-03